NK cells have been utilized for the treatment of cancer in patients with varying success, including mismatch of NK inhibitory receptor and MHC ligand interactions in the context of HCT, NK cell adoptive immunotherapy, and administration of antibodies, cytokines, or drugs aimed at enhancing NK cell function (7–9). This evidence concerns the gene HLA-C and cancer.